Table 2.
Variables | Number | Univariate Analysis (p Value) | Multivariate Analysis | ||
---|---|---|---|---|---|
HR | 95% CI | p Value | |||
Age ≥ 71 years, yes/no | 60/105 | <0.0001 | 2.110 | 0.919–4.950 | 0.0783 |
Gender, male/female | 93/72 | 0.2684 | |||
Presence of HCC, yes/no | 68/97 | <0.0001 | 4.527 | 1.833–12.320 | 0.0008 |
Total bilirubin ≥ 0.8 mg/dL, yes/no | 97/68 | 0.3132 | |||
Serum albumin ≥ 3.5 g/dL, yes/no | 122/43 | <0.0001 | 0.910 | 0.439–1.885 | 0.7975 |
Prothrombin time ≥ 76%, yes/no | 112/53 | <0.0001 | 0.816 | 0.410–1.621 | 0.5611 |
Platelet count ≥ 9.6 × 104/mm3, yes/no | 116/49 | 0.0067 | 0.697 | 0.313–1.554 | 0.3761 |
Hyaluronic acid ≥ 265 ng/mL, yes/no | 59/96 | <0.0001 | 1.942 | 0.890–4.382 | 0.0964 |
WFA+-M2BP ≥ 6.15 COI, yes/no | 69/96 | <0.0001 | 2.870 | 1.242–6.940 | 0.0132 |
APRI ≥ 1.27615, yes/no | 92/73 | 0.0552 | |||
FIB-4 index ≥ 4.97755, yes/no | 80/85 | 0.0007 | 1.649 | 0.681–4.336 | 0.2758 |
Achievement of an SVR, yes/no | 68/97 | <0.0001 | 23.833 | 4.579–439.545 | <0.0001 |
AST ≥ 55 IU/L, yes/no | 76/79 | 0.0595 | |||
ALT ≥ 20 IU/L, yes/no | 148/17 | 0.3304 | |||
ALP ≥ 317 IU/L, yes/no | 68/97 | <0.0001 | 1.161 | 0.545–2.553 | 0.7022 |
GGT ≥ 58 IU/L, yes/no | 49/116 | 0.1018 | |||
AFP ≥ 10.8 ng/mL, yes/no | 82/83 | <0.0001 | 1.426 | 0.659–3.318 | 0.3768 |
DCP ≥ 41 mAU/mL, yes/no # | 37/120 | <0.0001 | 3.543 | 1.602–7.976 | 0.0018 |
MELD score ≥ 5.1, yes/no | 55/110 | 0.0006 | 1.471 | 0.760–2.874 | 0.2521 |
HCC, hepatocellular carcinoma; WFA+-M2BP, Wisteria floribunda agglutinin-positive Mac-2-binding protein; COI, cutoff index; APRI, aspartate aminotransferase to platelet ration index; SVR, sustained virological response; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase; AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin; MELD, model for end-stage liver disease; #, missing data (n = 8); HR, hazard ratio; CI, confidence interval.